

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. **(Currently Amended)** A composition formulated for intramuscular injection comprising

a testosterone ester selected from the group of esters consisting of linear and branched noncanoates, decanoates, undecanoates, dodecanoates, tridecanoates, tetradecanoates, and pentadecanoates ~~C 9 to C 16 alkanates~~; and

a vehicle comprising castor oil in a concentration of 25 to 45% by volume and a co-solvent.
2. **(Canceled)**
3. **(Currently Amended)** The composition according to ~~claim 2~~ claim 1, wherein the testosterone ester is testosterone undecanoate.
4. **(Canceled)**
5. **(Original)** The composition according to claim 1, wherein the vehicle comprises said castor oil and co-solvent in a volume ratio ranging between 1:0.2 to 1:3.

6. (Original) The composition according to claim 1, wherein the co-solvent is benzyl benzoate.

7. – 20. (Canceled)

21. (Currently Amended) The composition according to claim 1, wherein the vehicle comprises the castor oil in a concentration of ~~less than~~ 25 to 40 vol%.

22. (Currently Amended) The composition according to claim 1, wherein the vehicle comprises the castor oil in a concentration of ~~less than~~ 25 to 30 vol%.

23. (Original) The composition according to claim 1, wherein the vehicle comprises said castor oil and co-solvent in a volume ratio ranging between 1:0.5 to 1:3.

24. (Original) The composition according to claim 1, wherein the vehicle comprises said castor oil and co-solvent in a volume ratio ranging between 1:0.75 to 1:2.5.

25. (Original) The composition according to claim 1, wherein the vehicle comprises said castor oil and co-solvent in a volume ratio ranging between 1:1 to 1:2.

26. – 28. (Canceled)

- 29. (New)** The composition according to claim 3, wherein the vehicle comprises the castor oil in a concentration of 25 to 40 vol%.
- 30. (New)** The composition according to claim 3, wherein the testosterone undecanoate is provided in the composition in a dose of 150 to 500 mg/ml.
- 31. (New)** The composition according to claim 30, wherein the vehicle comprises the castor oil in a concentration of 25 to 40 vol%.
- 32. (New)** The composition according to claim 1, wherein the cosolvent is in an amount of 55 to 65 vol% in the composition.
- 33. (New)** The composition according to claim 3, wherein the cosolvent is in an amount of 55 to 65 vol% in the composition.
- 34. (New)** The composition according to claim 30, wherein the vehicle comprises the castor oil in a concentration of 25 to 40 vol%.
- 35. (New)** The composition according to claim 3, wherein the co-solvent is benzyl benzoate.
- 36. (New)** The composition according to claim 30, wherein the co-solvent is benzyl

benzoate.

37. (New) The composition according to claim 1 in a form for single injection which contains 1000 mg of testosterone undecanoate in a vehicle containing 4 ml of a mixture of castor oil and benzyl benzoate in a ratio of 1:1.7 by volume

38. (New) A method for male contraception in a man comprising administering to the man by intramuscular injection, an effective amount of a composition according to claim 1.

39. (New) A method for treating primary or secondary hypogonadism in a man comprising administering to the man by intramuscular injection, an effective amount of a composition according to claim 1.

40. (New) The method of claim 39, wherein primary hypogonadism is treated and said primary hypogonadism is derived from: testicular failure selected from the group consisting of cryptorchidism, bilateral testicular torsion, orchitis, orchidectomy, Klinefelter syndrome, chemotherapy and toxic damage from alcohol or heavy metals.

41. (New) The method of claim 39, wherein secondary hypogonadism is treated and said secondary hypogonadism is derived from idiopathic gonadotropin releasing hormone (GnRH) deficiency or pituitary-hypothalamic injury caused by tumours, trauma or radiation.

42. (New) A method for treating a disease or symptom associated with a deficient level of testosterone in a man who is in therapy with a progestin or a gonadotropin suppressive agent, comprising administering to the man by intramuscular injection, an effective amount of a composition according to claim 1.

43. (New) The method of claim 41, wherein said deficient level of testosterone is such that the concentration of testosterone in serum of the man is less than 10 nmol/l.

44. (New) The method of claim 38, wherein the testosterone ester is testosterone undecanoate.

45. (New) The method of claim 39, wherein the testosterone ester is testosterone undecanoate.

46. (New) The method of claim 42, wherein the testosterone ester is testosterone undecanoate.

47. (New) The method of claim 38, wherein the composition is administered to provide the testosterone ester in a 6-week dose of 500 mg to 2000 mg, a 9-week dose of 500 mg to 2000 mg, a 10-week dose of 500 mg to 2000 mg, an 11-week dose of 500 mg to 2000 mg, a 12-week dose of 500 mg to 2000 mg, a 13-week dose of 500 mg to 2000 mg, a 14-week dose of 500 to 2000 mg, a 15-week dose of 500 to 2000 mg or a 16-week dose of 500 mg to 2000 mg.

48. (New) The method of claim 39, wherein the composition is administered to provide the testosterone ester in a 6-week dose of 500 mg to 2000 mg, a 9-week dose of 500 mg to 2000 mg, a 10-week dose of 500 mg to 2000 mg, an 11-week dose of 500 mg to 2000 mg, a 12-week dose of 500 mg to 2000 mg, a 13-week dose of 500 mg to 2000 mg, a 14-week dose of 500 to 2000 mg, a 15-week dose of 500 to 2000 mg or a 16-week dose of 500 mg to 2000 mg.

49. (New) The method of claim 42, wherein the composition is administered to provide the testosterone ester in a 6-week dose of 500 mg to 2000 mg, a 9-week dose of 500 mg to 2000 mg, a 10-week dose of 500 mg to 2000 mg, an 11-week dose of 500 mg to 2000 mg, a 12-week dose of 500 mg to 2000 mg, a 13-week dose of 500 mg to 2000 mg, a 14-week dose of 500 to 2000 mg, a 15-week dose of 500 to 2000 mg or a 16-week dose of 500 mg to 2000 mg.

50. (New) The method of claim 47, wherein said 6-, 9-, 10-, 11-, 12-, 13-, 14-, 15- or 16-week dose is of 750 mg to 1500 mg of the testosterone ester.

51. (New) The method of claim 48, wherein said 6-, 9-, 10-, 11-, 12-, 13-, 14-, 15- or 16-week dose is of 750 mg to 1500 mg of the testosterone ester.

52. (New) The method of claim 49, wherein said 6-, 9-, 10-, 11-, 12-, 13-, 14-, 15- or 16-week dose is of 750 mg to 1500 mg of the testosterone ester.

- 53. (New)** The method of claim 38, wherein the co-solvent is benzyl benzoate.
- 54. (New)** The method of claim 39, wherein the co-solvent is benzyl benzoate.
- 55. (New)** The method of claim 42, wherein the co-solvent is benzyl benzoate.
- 56. (New)** The composition of claim 1, wherein the composition contains no plant oil other than castor oil.